About the company
Insmed Inc is a leading global biopharmaceutical company at the forefront of developing innovative treatments for patients suffering from serious and rare diseases. With a strong commitment to improving patient outcomes, Insmed focuses on developing and commercializing therapeutic solutions that address unmet medical needs. One of Insmed's key achievements is the development and commercialization of ARIKAYCE (amikacin liposome inhalation suspension). ARIKAYCE is the company's first commercial product and has been approved by the US Food and Drug Administration (FDA) for the treatment of Mycobacterium Avium Complex (MAC) lung disease. MAC lung disease is a serious condition caused by a group of bacteria that can lead to chronic lung infections. ARIKAYCE is used as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. By targeting the specific bacteria responsible for MAC lung disease and delivering the medication directly to the lungs, ARIKAYCE offers a much-needed treatment option for patients. In addition to ARIKAYCE, Insmed has an exciting pipeline of earlier-stage clinical programs. One such program is Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme that plays a key role in the activation of neutrophils, which are a type of white blood cell involved in the inflammation process. By inhibiting DPP1, Brensocatib has the potential to reduce inflammation in various diseases, including non-cystic fibrosis bronchiectasis and other inflammatory lung diseases. This unique mechanism of action positions Brensocatib as a promising therapeutic option for patients who currently have limited treatment options. Another promising candidate in Insmed's pipeline is INS1009, an inhaled formulation of a treprostinil prodrug. Treprostinil is a prostacyclin analog that dilates blood vessels and improves blood flow. It is currently used as an intravenous or subcutaneous therapy for pulmonary arterial hypertension (PAH), a debilitating condition characterized by high blood pressure in the arteries of the lungs. However, the current routes of administration for treprostinil have limitations, including the need for continuous infusion or frequent injections. INS1009 aims to overcome these limitations by providing an inhaled formulation that may offer a differentiated product profile for the treatment of PAH. Overall, Insmed Inc is dedicated to transforming the lives of patients with serious and rare diseases through the development of innovative therapies. With its first commercial product, ARIKAYCE, and a robust pipeline of promising candidates such as Brensocatib and INS1009, the company is poised to make a significant impact in the field of biopharmaceuticals. By addressing unmet medical needs and providing novel treatment options, Insmed is improving patient outcomes and bringing hope to those in need.
Website: https://www.insmed.com
Data updated: May 5, 2026
